Lataa...
Pembrolizumab for the treatment of advanced melanoma
INTRODUCTION: Since 2010 multiple targeted therapies and immunotherapies have been approved for the treatment of advanced melanoma. Pembrolizumab, a humanized monoclonal antibody directed against programed death receptor 1 has shown significant activity in advanced melanoma resulting in its approval...
Tallennettuna:
| Julkaisussa: | Expert Opin Orphan Drugs |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5010088/ https://ncbi.nlm.nih.gov/pubmed/27597930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21678707.2016.1191348 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|